Bipsee raises Series A extension for VR digital therapy
What's the deal? Tokyo-based BipseeDealroom has a profile for this one. Try Dealroom → has completed the second close of its Series A through a third-party allotment of new shares to funds operated by JIC Venture Growth InvestmentsDealroom has a profile for this one. Try Dealroom → and Kyoto University Innovation CapitalDealroom has a profile for this one. Try Dealroom →. Including a 2023 grant from Japan's NEDODealroom has a profile for this one. Try Dealroom →, Bipsee says cumulative funding has reached ¥990 million.
What's the endgame? Bipsee is developing VR digital therapy using VR headsets and a smartphone app for depression and other psychiatric conditions. The company is focused on rumination, the tendency to repeatedly dwell on negative thoughts.
Why now? The new capital will support an ongoing confirmatory clinical trial for the therapy and preparations for regulatory approval. Bipsee completed an exploratory trial with Kochi University in 2025, and Japan's Ministry of Health, Labour and WelfareDealroom has a profile for this one. Try Dealroom → has designated the therapy for priority review as a program medical device.
The signal: Bipsee's raise reflects institutional interest in digital therapeutics as Japan seeks new ways to expand access to mental-health treatment and ease pressure on clinical teams. The product remains unapproved, and regulatory clearance depends on the results of the confirmatory trial.
Read more: PR TIMES
Image credit: Bipsee
